GlassScriptPhysician profile
Michael S Disiena
NPI 1932593837
$39,475.79
in general payments reported to CMS, 2019-2025
18 companies · $6,846 in 2025
The $6,846 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.65 · 2021: $179 · 2022: $1,200 · 2023: $4,836 · 2024: $26K · 2025: $6,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $6,159 · Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,030.00 |
| Travel and Lodging | $6,159.23 |
| Food and Beverage | $1,892.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $26,784.89 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $5,991.47 | 2023-2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $4,846.15 | 2022-2025 | Dupixent |
| Abbvie INC. | $506.31 | 2021-2025 | Rinvoq |
| Ucb, INC. | $378.80 | 2022-2023 | Bimzelx |
| Genzyme Corporation | $293.78 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.00 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Dermavant Sciences, INC. | $100.27 | 2022 | |
| Janssen Biotech, INC. | $73.97 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Regeneron Pharmaceuticals, INC. | $70.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.71 | 2022-2024 | Xifaxan |
| Celgene Corporation | $54.00 | 2021-2022 | |
| Intra-Sana Laboratories | $19.26 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Nestle Healthcare Nutrition INC. | $17.66 | 2023 | |
| Gilead Sciences, INC. | $16.82 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $15.86 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.39 | 2022 | |
| Lilly USA, LLC | $13.15 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Disiena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.